Adjuvant trastuzumab for breast cancer: assessing HER2/neu status incurs more costs for treatment.
Kell
Malcolm R
MR
Power
Colm P
CP
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000235:genetics*; D017024:Chemotherapy, Adjuvant; D005260:Female; D018734:Genes, erbB-2; D006801:Humans; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab